Soligenix
29 Emmons Drive
Suite C-10
Princeton
New Jersey
08540
United States
Tel: 609-538-8200
Fax: 609-452-6467
Website: http://www.soligenix.com/
322 articles with Soligenix
-
Soligenix and the European Medicines Agency Pediatric Committee Reach Agreement on the Pediatric Investigation Plan for SGX942
4/9/2019
Acceptance of Pediatric Investigation Plan is important milestone on the path to submission of Marketing Authorization Application in Europe
-
Soligenix Receives US Patent for Dusquetide Related Analogs
4/4/2019
Patent broadens protection in infectious disease and oral mucositis, including composition of matter claims
-
Soligenix Announces Recent Accomplishments and Year-End 2018 Financial Results
3/26/2019
Soligenix, Inc. announced its recent accomplishments and financial results for the year ended December 31, 2018.
-
Soligenix Announces Recent Accomplishments And Year-End 2018 Financial Results - March 26, 2019
3/26/2019
Soligenix, Inc announced its recent accomplishments and financial results for the year ended December 31, 2018.
-
Soligenix to Present at National Institutes of Health - Commercialization Accelerator Program "FeedForward Session" in Washington, DC
3/18/2019
Soligenix, Inc. announced that they will be presenting at the National Institutes of Health - Commercialization Accelerator Program "FeedForward Session" in Washington, DC on March 21, 2019.
-
Soligenix to Present at National Institutes of Health - Commercialization Accelerator Program "FeedForward Session" in Washington, DC
3/18/2019
Soligenix, Inc. announced today that they will be presenting at the National Institutes of Health (NIH) – Commercialization Accelerator Program (CAP) "FeedForward Session" in Washington, DC on March 21, 2019.
-
Soligenix to Present at the Boston Oncology Investor Conference 2019
3/11/2019
Soligenix, Inc. announced that its Chief Scientific Officer, Oreola Donini, PhD, will deliver a corporate presentation at the Boston Oncology Investor Conference 2019 on Thursday, March 14 at 5:35 PM ET.
-
Soligenix Corporate Presentation Webcast Recording
2/25/2019
An updated webcast of the Soligenix Corporate Presentation, given by Dr. Christopher J. Schaber, President and CEO, is available on the Company website. To listen and view the presentation, please visit www.soligenix.com.
-
Zack's Investment Research, Inc. Research Report Update on Soligenix
2/12/2019
Analyst David Bautz, PhD of Zack's Investment Research, Inc. updated coverage on Soligenix, Inc. on February 12, 2019. For more information, please visit SCR.Zacks.com.
-
Soligenix Receives US Patent Expanding Protection for its Ricin Toxin Vaccine, RiVax®
2/11/2019
Soligenix, Inc. announced the allowance of a new United States patent protecting its ricin toxin vaccine, RiVax®.
-
Soligenix Receives US Patent Expanding Protection for its Ricin Toxin Vaccine, RiVax®
2/11/2019
Soligenix, Inc. announced the allowance of a new United States patent protecting its ricin toxin vaccine, RiVax®.
-
Soligenix Announces Publication Demonstrating Thermostabilization of an Ebola Subunit Vaccine Candidate
2/7/2019
Soligenix, Inc. announced publication of a scientific article demonstrating the successful thermostabilization of an Ebola subunit vaccine candidate.
-
Although bioterrorism doesn’t get the kind of attention more traditional bombings and shootings receive, the biotech industry and the federal government are paying attention and actively funding and developing countermeasures to potential bioterror, military and public health emergencies.
-
Soligenix Receives European Patent for Dusquetide and Related Innate Defense Regulator Analogs
1/23/2019
Patent broadens protection in infectious disease, including composition of matter claims
-
Patent broadens protection in infectious disease, including composition of matter claims
1/23/2019
Patent broadens protection in infectious disease, including composition of matter claims [23-January-2019] PRINCETON, N.J. , Jan. 23, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical n
-
Soligenix to Receive $611,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program
12/11/2018
Soligenix, Inc. announced today that it has received preliminary approval for a tax credit from the New Jersey Economic Development Authority's (NJEDA) New Jersey Technology Business Tax Certificate Transfer program.
-
Maxim Group Research Report Update on Soligenix
12/6/2018
Analyst Jason McCarthy, PhD of Maxim Group updated coverage on Soligenix, Inc. on December 6, 2018. For more information, please visit www.maximgrp.com.
-
Soligenix Announces Publication of Scientific Review Discussing Clinical Applications of Innate Defense Regulator Technology
12/5/2018
Highlights Potential for Treating Multiple Diseases with Dusquetide and Related IDR Analogs
-
Soligenix Selected to Present RiVax® Data at the Fourth International Conference on Vaccines Research & Development in Baltimore, Maryland
11/12/2018
Soligenix, Inc. announced that Dr. Oreola Donini, Chief Scientific Officer, will be presenting data from the ricin toxin vaccine (RiVax®) program describing development of the vaccine under the Food and Drug Administration (FDA) Animal Rule.
-
Soligenix Announces Recent Accomplishments And Third Quarter 2018 Financial Results
11/9/2018
Soligenix, Inc. announced today its recent accomplishments and financial results for the third quarter ended September 30, 2018.